Equities analysts expect FibroGen Inc (NASDAQ:FGEN) to post $35.09 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for FibroGen’s earnings, with the highest sales estimate coming in at $46.80 million and the lowest estimate coming in at $28.93 million. FibroGen posted sales of $191.57 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 81.7%. The business is scheduled to report its next earnings results on Thursday, August 13th.
According to Zacks, analysts expect that FibroGen will report full year sales of $257.38 million for the current financial year, with estimates ranging from $241.28 million to $282.00 million. For the next financial year, analysts expect that the company will post sales of $431.74 million, with estimates ranging from $322.94 million to $495.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for FibroGen.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.50). FibroGen had a negative return on equity of 19.32% and a negative net margin of 42.75%. The business had revenue of $24.40 million for the quarter, compared to the consensus estimate of $72.58 million. During the same period in the previous year, the business posted ($0.53) earnings per share. FibroGen’s revenue was up 2.3% on a year-over-year basis.
FGEN stock traded up $1.37 during trading on Wednesday, hitting $43.50. 536,400 shares of the stock traded hands, compared to its average volume of 719,138. FibroGen has a one year low of $22.65 and a one year high of $48.95. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of -32.95 and a beta of 1.58. The company has a 50 day simple moving average of $37.25 and a 200 day simple moving average of $39.18. The company has a current ratio of 11.14, a quick ratio of 11.01 and a debt-to-equity ratio of 0.07.
In other FibroGen news, CFO Pat Cotroneo sold 3,928 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $39.68, for a total value of $155,863.04. Following the transaction, the chief financial officer now directly owns 271,060 shares in the company, valued at $10,755,660.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Enrique A. Conterno purchased 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average price of $36.29 per share, for a total transaction of $290,320.00. Following the completion of the purchase, the chief executive officer now directly owns 60,000 shares of the company’s stock, valued at approximately $2,177,400. The disclosure for this purchase can be found here. Corporate insiders own 3.39% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the stock. Neo Ivy Capital Management purchased a new position in shares of FibroGen during the fourth quarter worth about $30,000. NumerixS Investment Technologies Inc purchased a new position in shares of FibroGen during the fourth quarter worth about $51,000. Ameritas Investment Company LLC purchased a new position in shares of FibroGen during the first quarter worth about $61,000. Islay Capital Management LLC purchased a new position in shares of FibroGen during the fourth quarter worth about $82,000. Finally, Arden Trust Co bought a new stake in FibroGen in the 1st quarter worth approximately $115,000. Institutional investors and hedge funds own 71.66% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: Diversification in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.